DOCSLIB.ORG

EMTN-2020-Prospectus.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
EMTN-2020-Prospectus.Pdf Prospectus JYSKE BANK A/S (incorporated as a public limited company in Denmark) U.S.$8,000,000,000 Euro Medium Term Note Programme On 22 December 1997, the Issuer (as defined below) entered into a U.S.$1,000,000,000 Euro Medium Term Note Programme (the “Programme”). This document supersedes the Prospectus dated 11 June 2019 and any previous Prospectus and/or Offering Circular. Any Notes (as defined below) issued under the Programme on or after the date of this Prospectus are issued subject to the provisions described herein. This Prospectus does not affect any Notes issued before the date of this Prospectus. Under the Programme, Jyske Bank A/S (the “Issuer”, “Jyske Bank” or the “Bank”) may from time to time issue notes (the ”Notes”), which may be (i) preferred senior notes (“Preferred Senior Notes”), (ii) non-preferred senior notes (“Non-Preferred Senior Notes”), (iii) subordinated and, on issue, constituting Tier 2 Capital (as defined in the Terms and Conditions of the Notes) (“Subordinated Notes”) or (iv) subordinated and, on issue, constituting Additional Tier 1 Capital (as defined in the Terms and Conditions of the Notes) (“Additional Tier 1 Capital Notes”) as indicated in the applicable Final Terms (as defined below). Notes may be denominated in any currency (including euro) agreed between the Issuer and the relevant Dealer (as defined below). The maximum aggregate principal amount of all Notes from time to time outstanding under the Programme will not exceed U.S.$8,000,000,000 (or its equivalent in other currencies calculated as described herein), subject to any increase as described herein. The Notes may be issued on a continuing basis to one or more of the Dealers specified on page 8 and any additional Dealer appointed under the Programme from time to time, which appointment may be for a specific issue of Notes or on an ongoing basis (each, a “Dealer” and together, the “Dealers”). References in this Prospectus to the “relevant Dealer” shall, in the case of an issue of Notes being (or intended to be) subscribed by one or more Dealers, be to all Dealers agreeing to purchase such Notes. The Issuer has reserved the right to issue Notes to persons other than Dealers. This Prospectus has been approved by the Central Bank of Ireland, as competent authority under the Prospectus Regulation (as defined below). The Central Bank of Ireland only approves this Prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. Such approval should not be considered as an endorsement of the Issuer or of the quality of the Notes. Investors should make their own assessment as to the suitability of investing in the Notes. Such approval relates only to Notes that are to be admitted to trading on the regulated market (the “Regulated Market”) of the Irish Stock Exchange plc trading as Euronext Dublin (“Euronext Dublin”) or on another regulated market in the European Economic Area (which, for these purposes, included the United Kingdom) for the purposes of Directive 2014/65/EU (as amended) (“MiFID II”) and/or that are to be offered to the public in any member state of the European Economic Area (which, for these purposes, includes the United Kingdom) in circumstances that require the publication of a prospectus. Application has been made to Euronext Dublin for Notes issued under the Programme during the period of 12 months from the date of this Prospectus to be admitted to the official list of Euronext Dublin (the “Official List”) and admitted to trading on the Regulated Market. The Regulated Market is a regulated market for the purposes of MiFID II. References in this Prospectus to Notes being “listed” (and all related references) shall mean that such Notes have been admitted to the Official List and admitted to trading on the Regulated Market. This Prospectus (as supplemented as at the relevant time, if applicable) is valid for 12 months from its date in relation to Notes which are to be admitted to trading on a regulated market for the purposes of MiFID II in the European Economic Area (which, for these purposes, includes the United Kingdom). The obligation to supplement this Prospectus in the event of a significant new factor, material mistake or material inaccuracy does not apply when this Prospectus is no longer valid. Notice of: (i) the aggregate principal amount of; (ii) interest (if any) payable in respect of; (iii) the issue price of; and (iv) certain other information which is applicable to, the Notes of each Tranche (as defined in the Terms and Conditions of the Notes (the “Conditions”) below) will be set out in a final terms document (the “Final Terms”) which will be delivered to the Central Bank of Ireland and Euronext Dublin (if listed on Euronext Dublin). Copies of Final Terms in relation to Notes to be listed on Euronext Dublin will also be published on the website of Euronext Dublin at www.ise.ie. The Notes of each Tranche in bearer form will initially be represented by a temporary global Note in bearer form or a permanent global Note in bearer form (together, the “Global Notes”). If the Global Notes are stated in the applicable Final Terms to be issued in new global note (“NGN”) form they will be delivered on or prior to the original issue date of the relevant Tranche to a common safekeeper (the “Common Safekeeper”) for Euroclear Bank SA/NV (“Euroclear”) and Clearstream Banking S.A. (“Clearstream, Luxembourg”). Notes in registered form will be represented by registered certificates (each a “Certificate”), one Certificate being issued in respect of each Noteholder’s (as defined in the Conditions) entire holding of Registered Notes of one Series (as defined in the Conditions). Registered Notes issued in global form will be represented by registered global certificates (“Global Certificates”). If a Global Certificate is held under the New Safekeeping Structure (the “NSS”) the Global Certificate will be delivered on or prior to the original issue date of the relevant Tranche to a Common Safekeeper for Euroclear and Clearstream, Luxembourg. Global Notes which are not issued in NGN form (“Classic Global Notes” or “CGNs”) and Global Certificates which are not held under the NSS will be deposited on the issue date thereof with a common depositary on behalf of Euroclear and Clearstream, Luxembourg and/or any other agreed clearance system specified in the applicable Final Terms (the “Common Depositary”). Each temporary global Note will be exchangeable, as specified in the applicable Final Terms, for either a permanent global Note or Notes in definitive form, in each case upon certification as to non-US beneficial ownership as required by US Treasury regulations. A permanent global Note will be exchangeable for definitive Notes in limited circumstances, all as further described in “Summary of Provisions relating to Notes while in Global Form” herein. If so specified in the applicable Final Terms, Notes may also be issued in uncertificated and dematerialised book entry form, settled through VP SECURITIES A/S (the “VP”) (the “VP Notes”). For the purposes of Regulation (EC) No. 1060/2009 on credit rating agencies (as amended) (the “CRA Regulation”), the credit ratings included or referred to in this Prospectus have been issued by S&P Global Ratings Europe Limited (“S&P”). S&P is established in the European Union and is registered under the CRA Regulation. Tranches of Notes to be issued under the Programme will be rated or unrated. Where a Tranche of Notes is to be rated, such rating will be specified in the applicable Final Terms. The ratings may not reflect the potential impact of all risks related to structure, market and other factors that may affect the value of the Notes. A rating is not a recommendation to buy, sell or hold securities and may be subject to revision, suspension or withdrawal at any time by the assigning rating agency. Prospective investors should have regard to the factors described under the section headed “Risk Factors” in this Prospectus. Arranger J.P. Morgan Dealers BNP PARIBAS Deutsche Bank Goldman Sachs International ING J.P. Morgan Jyske Bank A/S Landesbank Baden-Württemberg Dated 24 August 2020 This Prospectus comprises a base prospectus for the purposes of Article 8 of the Prospectus Regulation and for the purposes of giving information with regard to the Issuer together with its consolidated subsidiaries (the “Jyske Bank Group” or the “Group”) and the Notes which, according to the particular nature of the Issuer and the Notes, is necessary information which is material to an investor for making an informed assessment of the assets and liabilities, financial position, profit and losses and prospects of the Issuer, the rights attaching to the Notes and the reasons for the issuance and its impact on the Issuer. When used in this Prospectus, “Prospectus Regulation” means Regulation (EU) 2017/1129. The Issuer accepts responsibility for the information contained in this Prospectus and the Final Terms for each Tranche of Notes issued under the Programme. To the best of the knowledge of the Issuer, the information contained in this Prospectus is in accordance with the facts and does not omit anything likely to affect the import of such information. This Prospectus is to be read in conjunction with all documents which are deemed to be incorporated herein by reference (see “Documents Incorporated by Reference”). Other than in relation to the documents which are deemed to be incorporated by reference (see “Documents Incorporated by Reference”), the information on the websites to which this Prospectus refers does not form part of this Prospectus and has not been scrutinised or approved by the Central Bank of Ireland.
Load more

Recommended publications
  • Jyske Bank H1 2014 Agenda
    Jyske Bank H1 2014 Agenda • Jyske Bank in brief • Jyske Banks Performance 1968-2013 • Merger with BRFkredit • Focus in H1 2014 • H1 2014 in figures • Capital Structure • Liquidity • Credit Quality • Strategic Issues • Macro Economy & Danish Banking 2013-2015 • Danish FSA • Fact Book 2 Jyske Bank in brief 3 Jyske Bank in brief Jyske Bank focuses on core business Description Branch Network • Established and listed in 1967 • 2nd largest Danish bank by lending • Total lending of DKK 344bn • 149 domestic branches • Approx. 900,000 customers • Business focus is on Danish private individuals, SMEs and international private and institutional investment clients • International units in Hamburg, Zürich, Gibraltar, Cannes and Weert • A de-centralised organisation • 4,352 employees (end of H1 2013) • Full-scale bank with core operations within retail and commercial banking, mortgage financing, customer driven trading, asset management and private banking • Flexible business model using strategic partnerships within life insurance (PFA), mortgage products (DLR), credit cards (SEB), IT operations (JN Data) and IT R&D (Bankdata) 4 Jyske Bank in brief Jyske Bank has a differentiation strategy “Jyske Differences” • Jyske Bank wants to be Denmark’s most customer-oriented bank by providing high standard personal financial advice and taking a genuine interest in customers • The strategy is to position Jyske Bank as a visible and distinct alternative to more traditional providers of financial services, with regard to distribution channels, products, branches, layout and communication forms • Equal treatment and long term relationships with stakeholders • Core values driven by common sense • Strategic initiatives: Valuebased management Differentiation Risk management Efficiency improvement Acquisitions 5 1990 1996 2002 2006 (Q4) 2011/2012 Jyske Bank performance 1968-2013 6 ROE on opening equity – 1968-2013 Pre-tax profit Average: (ROE on open.
    [Show full text]
  • Retirement Strategy Fund 2060 Description Plan 3S DCP & JRA
    Retirement Strategy Fund 2060 June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA ACTIVIA PROPERTIES INC REIT 0.0137% 0.0137% AEON REIT INVESTMENT CORP REIT 0.0195% 0.0195% ALEXANDER + BALDWIN INC REIT 0.0118% 0.0118% ALEXANDRIA REAL ESTATE EQUIT REIT USD.01 0.0585% 0.0585% ALLIANCEBERNSTEIN GOVT STIF SSC FUND 64BA AGIS 587 0.0329% 0.0329% ALLIED PROPERTIES REAL ESTAT REIT 0.0219% 0.0219% AMERICAN CAMPUS COMMUNITIES REIT USD.01 0.0277% 0.0277% AMERICAN HOMES 4 RENT A REIT USD.01 0.0396% 0.0396% AMERICOLD REALTY TRUST REIT USD.01 0.0427% 0.0427% ARMADA HOFFLER PROPERTIES IN REIT USD.01 0.0124% 0.0124% AROUNDTOWN SA COMMON STOCK EUR.01 0.0248% 0.0248% ASSURA PLC REIT GBP.1 0.0319% 0.0319% AUSTRALIAN DOLLAR 0.0061% 0.0061% AZRIELI GROUP LTD COMMON STOCK ILS.1 0.0101% 0.0101% BLUEROCK RESIDENTIAL GROWTH REIT USD.01 0.0102% 0.0102% BOSTON PROPERTIES INC REIT USD.01 0.0580% 0.0580% BRAZILIAN REAL 0.0000% 0.0000% BRIXMOR PROPERTY GROUP INC REIT USD.01 0.0418% 0.0418% CA IMMOBILIEN ANLAGEN AG COMMON STOCK 0.0191% 0.0191% CAMDEN PROPERTY TRUST REIT USD.01 0.0394% 0.0394% CANADIAN DOLLAR 0.0005% 0.0005% CAPITALAND COMMERCIAL TRUST REIT 0.0228% 0.0228% CIFI HOLDINGS GROUP CO LTD COMMON STOCK HKD.1 0.0105% 0.0105% CITY DEVELOPMENTS LTD COMMON STOCK 0.0129% 0.0129% CK ASSET HOLDINGS LTD COMMON STOCK HKD1.0 0.0378% 0.0378% COMFORIA RESIDENTIAL REIT IN REIT 0.0328% 0.0328% COUSINS PROPERTIES INC REIT USD1.0 0.0403% 0.0403% CUBESMART REIT USD.01 0.0359% 0.0359% DAIWA OFFICE INVESTMENT
    [Show full text]
  • Aktienyt Novozymes
    Aktienyt Novozymes Hold Udfordrende markeder dæmper salgsvæksten Uændret Hold-anbefaling siden 20/04/2016 Vi fastholder vores Hold-anbefaling på Novozymes Dagens regnskab er lidt svagere, end vi havde ventet. Hård priskonkurrence i ’Bioenergi’ og økonomisk Analysedato: 10/08/2016 pressede kunder i ’Landbrug og Foder’ dæmper Novozymes’ salgsvækst. Pris- fastsættelsen af Novozymes-aktien afspejler efter vores vurdering Novozymes’ Aktuel kurs kl. 12:11: kortsigtede forretningsmuligheder. 295,00 DKK Salgsvæksten skuffer i årets 2. kvartal Omsætningen på 3.429 mio. kr. i 2. kvartal 2016 er 3,3% dårligere end vores estimat (-3,5% i Begivenhed: forhold til markedsforventningen). Resultatet af primær drift på 961 mio. kr. i 2. kvartal 2016 er 2,9% under vores estimat (-2,6% i forhold til markedsforventningen). I forhold til vores for- 2. kvartalsregnskab ventning er det specielt salget i divisionerne ’Bioenergi’ og ’Landbrug og Foder’, der viser en svagere end ventet udvikling i 2. kvartal. Novozymes justerer salgsprognosen for 2016 i lokal Seneste analyse: valuta. Selskabet venter nu en salgsvækst i lokal valuta på 2-4% i 2016 mod tidligere 3-5%. 05/08/16 – Vækst i ’Vaskemid- Novozymes forventer, at salgsvæksten i danske kroner forbliver uændret på 1-3% i 2016. ler’ – Tilbagegang i ’Bioenergi’ Salgsvæksten i ’Vaskemidler’ overgår vores forventning Den organiske salgsvækst i divisionen ’Vaskemidler’ på 4% i 2. kvartal er lidt bedre end vo- res estimat på 3%. Vi hæfter hos ved, at salget vokser i Asien drevet af øget penetration af Kalender: enzymer i flydende vaskemidler. Yderligere noterer vi os, at den positive salgsudvikling er 26/10/16 – 3.
    [Show full text]
  • Aktiekommentar Novozymes
    Aktiekommentar Novozymes Sælg Novozymes står på dørtærsklen til et kommercielt Uændret gennembrud i 2G-biobrændstofindustrien Aktuel kurs: 216,30 DKK Begivenhed: Vi fastholder Sælg-anbefalingen på Novozymes. Værdiansættelsen af Novozy- mes-aktien indregner efter vores vurdering allerede store forventninger til Novo- zymes’ fremtidige salg og indtjening fra 2G-biobrændstofenzymer. 2G-industrien Optakt til kapitalmar- er dog i sin spæde opstartsfase. Der er fortsat stor usikkerhed forbundet med kedsdag hvilke teknologiske løsninger, der vil blive markedsledende. Vi forventer dog, at Novozymes vil få en betydelig markedsposition som leverandør til 2G-industrien. Baggrund: Novozymes afholder kapitalmarkedsdag den 31. oktober 2013. Det overordnende tema for dagen er anden generations biobrændstof (2G) og mulighederne for Novozymes i denne indu- stri. Verdens første kommercielle 2G-bioethanolproduktion er for nylig startet op i Cresentino i Italien med Novozymes som enzymleverandør. Produktionsanlægget er opført af italienske Beta Renewables, som Novozymes ejer 10% af. Konklusion: På kapitalmarkedsdagen vil vi have fokus på følgende punkter: - Produktionsøkonomien på det italienske 2G-anlæg – er det kommercielt konkurren- cedygtigt? - Statusopdatering på Novozymes’ globale partnerskabsaftaler – tidshorisont for kom- merciel 2G-produktion på forskellige markeder - Novozymes/Beta Renewables styrker i forhold til konkurrerende teknologier Vi forventer, at Novozymes i 2015 kan opnå et globalt enzymsalg til 2G- biobrændstofsproduktion på 213 mio. kr. stigende til 2.166 mio. kr. i 2020. Vi forventer, at Ki- na og Brasilien vil agere vækstmotor for udviklingen af 2G-industrien, mens vi først forventer, at udviklingen i USA kommer op i tempo efter 2015. Det er efter vores vurdering helt centralt, at Novozymes har indgået et samarbejde med itali- enske Beta Renewables.
    [Show full text]
  • Nykredit Realkredit Group Annual Report 2011
    Annual Report 2011 The Nykredit Realkredit Group CONTENTS ABOUT NYKREDIT MANAGEMENT STATEMENT AND AUDIT REPORTS Foreword 1 Management Statement 57 Company information 2 Internal Auditors' Report 58 Group chart 3 Independent Auditors' Report 59 Financial highlights 4 2011 – in brief 6 Outlook for 2012 6 FINANCIAL STATEMENTS 2011 Income statements 60 Statements of comprehensive income 61 MANAGEMENT'S REVIEW Balance sheets 62 Nykredit Realkredit group results 7 Statement of changes in equity 64 Results relative to forecasts 9 Capital base and capital adequacy 66 Outlook for 2012 9 Cash flow statement 67 Equity and capital adequacy 10 Core earnings and investment portfolio income 68 Events occurred after the end of the financial year 11 Notes 69 Business areas 12 New regulation 22 SERIES FINANCIAL STATEMENTS 138 Other 22 Group capital management 24 Capital policy and structure 24 OTHER INFORMATION Required capital base and internal capital adequacy requirement 24 Financial calendar for 2012 141 Stress tests and countercyclical buffer 25 Nykredit's Management 142 Organisation, management and corporate responsibility 26 Board of Directors 142 Financial sustainability and corporate responsibility 26 Executive Board 143 Strategy to strengthen growth in banking 26 Organisation and delegation of responsibilities 26 Corporate Governance 28 Staff 28 Internal control and risk management systems 29 Group risk management 31 Group characteristics 31 Credit risk 32 Market risk 35 Liquidity risk 38 Operational risk 38 Uncertainty as to recognition and measurement
    [Show full text]
  • Beholdningsoversigt 31.03.2021 Jyske Bank.Xlsx
    INSTRUMENT_TYPE ISIN ISSUER_NAME Formue Københavns Kommune i kr. 4.069.081.439,62 Equity GB00B0SWJX34 London Stock Exchange Group PLC 1.701.893,31 Equity GB00B24CGK77 Reckitt Benckiser Group PLC 3.564.881,56 Equity AU000000SYD9 Sydney Airport 1.337.059,47 Equity JP3435000009 Sony Corp 6.910.276,86 Equity US0091581068 Air Products and Chemicals Inc 3.520.243,74 Equity US87918A1051 Teladoc Health Inc 1.795.360,11 Equity NL0012169213 QIAGEN NV 1.219.259,56 Equity US12504L1098 CBRE Group Inc 1.615.018,42 Equity FR0013154002 Sartorius Stedim Biotech 1.136.250,30 Equity CH0432492467 Alcon Inc 1.661.975,62 Equity FR0000121667 EssilorLuxottica SA 2.339.599,76 Equity CH0010645932 Givaudan SA 2.497.439,42 Equity CH0013841017 Lonza Group AG 2.547.489,13 Equity FR0010533075 Getlink SE 1.081.032,87 Equity AU0000030678 Coles Group Ltd 1.716.338,55 Equity NO0003054108 Mowi ASA 988.624,03 Equity GB00BHJYC057 InterContinental Hotels Group PLC 1.324.892,92 Equity NL0013267909 Akzo Nobel NV 2.081.864,14 Equity CA12532H1047 CGI Inc 1.974.562,46 Equity SE0012455673 Boliden AB 1.168.396,04 Equity BMG475671050 IHS Markit Ltd 1.720.814,54 Equity CA82509L1076 Shopify Inc 5.815.734,65 Equity CA7677441056 Ritchie Bros Auctioneers Inc 1.079.486,62 Equity JP3198900007 Oriental Land Co Ltd/Japan 2.377.930,50 Equity US6516391066 Newmont Corp 3.214.940,55 Equity IE00BK9ZQ967 Trane Technologies PLC 1.962.517,98 Equity GB00B39J2M42 United Utilities Group PLC 1.586.616,23 Equity US0036541003 ABIOMED Inc 1.469.304,62 Equity US9553061055 West Pharmaceutical Services Inc 1.484.522,98
    [Show full text]
  • Annual Report 2019 Sydbank Group Preface
    Annual Report 2019 Sydbank Group Preface 4 SYDBANK / 2019 Annual Report 2019 characterised by growth in total credit intermediation and historically high remortgaging activity Sydbank’s 2019 financial statements show a profit before tax of DKK 1,081m compared to DKK 1,420m in 2018. The decrease of DKK 339m is mainly attributable to a drop in total income of DKK 210m and a change in non-re- 2019 highlights curring items of DKK 109m. Profit before tax equals a return of 9.7% p.a. on • A 5% decrease in total income average equity. • A 2% rise in costs (core earnings) • A reversal of DKK 97m in impairment charges Profit for the year after tax represents DKK 853m against DKK 1,161m in • A drop in core earnings of DKK 296m to DKK 1,193m 2018, equal to a return on average equity of 7.5%. At the beginning of 2019 • Negative investment portfolio earnings of DKK 61m profit after tax was projected to be in the range of DKK 800-1,100m. • Bank loans and advances of DKK 60.6bn CEO Karen Frøsig comments on the year’s result and the current strategy: • Total credit intermediation of DKK 145.1bn - It is good news that a sizeable improvement in total credit intermediation of • Deposits of DKK 84.3bn almost DKK 3bn has been recorded and that credit quality is still so good that • A capital ratio of 22.9%, including a CET1 ratio of 17.8% we were able to reverse impairment charges amounting to almost DKK 100m • A proposed dividend of DKK 5.70 per share in 2019.
    [Show full text]
  • Annual Report 2011 3) the Calculation Is Based on a Share Denomination of DKK 5
    Financial highlights Group 2011 2010 2009 2008 2007 2011 2011 DKKm DKKm DKKm DKKm DKKm EURm1 USDm2 Revenue 16,007 14,765 13,747 11,572 11,171 2,148 2,987 Research and development costs 3,320 3,045 3,196 2,990 2,193 446 620 Operating profit before depreciation and amortisation (EBITDA) 4,628 4,393 3,728 3,418 3,611 621 864 Profit from operations (EBIT) 3,393 3,357 2,858 2,354 2,689 455 633 Net financials (96) (68) (192) (28) 65 (13) (18) Profit for the year 2,282 2,466 2,007 1,663 1,881 306 426 Total assets 20,534 18,005 17,127 12,526 12,230 2,762 3,574 Equity 12,776 11,122 8,803 7,511 7,089 1,719 2,224 Cash flows from operating and investing activities 929 2,462 (2,040) 2,193 1,610 125 173 Investments in property, plant and equipment, gross 419 383 258 229 474 56 73 % % % % % % % EBITDA margin 28.9 29.8 27.1 29.5 32.3 28.9 28.9 EBIT margin 21.2 22.7 20.8 20.3 24.1 21.2 21.2 Return on capital employed 25.3 27.6 28.0 30.0 34.6 25.3 25.3 Return on equity 19.1 24.8 24.6 22.8 27.3 19.1 19.1 Research and development ratio 20.7 20.6 23.2 25.8 19.6 20.7 20.7 Solvency ratio 62.2 61.8 51.4 60.0 58.0 62.2 62.2 Capital turnover 78.0 82.0 80.3 92.4 91.3 78.0 78.0 Effective tax rate 30.8 25.0 24.7 27.1 29.6 30.8 30.8 DKK DKK DKK DKK DKK EUR1 USD2 Earnings per share (EPS)3 11.63 12.57 10.24 8.45 9.18 1.56 2.17 Diluted earnings per share (DEPS)3 11.63 12.57 10.24 8.45 9.17 1.56 2.17 Proposed dividend per share3 3.49 3.77 3.07 2.30 2.56 0.47 0.65 Cash flow per share3 18.48 16.65 15.47 14.12 13.18 2.48 3.45 Net asset value per share3 65.14 56.71 44.89
    [Show full text]
  • Aktieanalyse GN Store Nord
    AktieAnalyse GN Store Nord Hold Amerikanske orkaner giver modvind til GN Hea- Uændret Hold-anbefaling siden 09/05/2017 ring Analysedato: 02/11/2017 Vi fastholder Hold-anbefalingen på GN Store Nord. GN Audio leverer som ven- tet rigtige stærke resultater i 3. kvartal. Til gengæld hakker salgsvækstmotoren i GN Hearing en smule i årets 3. kvartal. Værdiansættelsen af GN Store Nord- Aktuel kurs kl. 12:54 aktien indregner efter vores vurdering allerede i store træk GN Store Nords 203,70 DKK vækstmuligheder på den korte bane. Begivenhed: 3. kvartalsregnskabet er stort set på linje med vores forventning Omsætningen på 2.282 mio. kr. i 3. kvartal 2017 er 1,8% lavere end vores estimat (-0,9% i 3. kvartalsregnskab forhold til markedsforventningen). Resultat af primær drift på 371 mio. kr. er 0,9% dårligere end vores estimat. I forhold til vores indtjeningsestimat er det GN Hearing, der ikke kan indfri Seneste analyse: vores forventninger i 3. kvartal. GN Store Nord løfter salgsprognosen i GN Audio i forbindel- se med 3. kvartalsregnskabet, så GN Audio nu forventer en organisk salgsvækst på ’mere 30/10/17 – GN Audio vil løfte end 7%’ mod tidligere ’mere end 6%’. Vi forventer, at GN Audio meget komfortabelt kan salgsprognosen i 3. kvartals- indfri den nye salgsprognose, som i vores øjne fortsat ser lidt konservativ ud. regnskabet Salgsvæksten i GN Hearing når ikke vores forventning i 3. kvartal Omsætningen i GN Hearing er 2,3% under vores estimat i 3. kvartal. GN Hearing realiserer Kalender: en organisk salgsvækst på 6% i 3. kvartal, hvilket er under vores estimat på 8% organisk salgsvækst.
    [Show full text]
  • Aktienyt Novozymes
    Aktienyt Novozymes Hold To cylindre i salgsvækstmotoren sætter ud Uændret Vi fastholder Hold-anbefalingen på Novozymes. Dagens regnskab byder på en Aktuel kurs: overraskende nedjustering af den organiske salgsvækst drevet af udfordringer inden for vaskemidler og bioenergi. Vi forventer ikke, at Novozymes vil være i 321,1 DKK stand til at løse udfordringerne på den korte bane. Begivenhed: Salgsvæksten skuffer markant i 2. kvartal Omsætningen på 3.449 mio. kr. i 2. kvartal 2015 er 5,2 % dårligere end vores estimat (-6,1% 2. kvartalsregnskab ift. markedsforventningerne). Resultatet af primær drift på 930 mio. kr. i 2. kvartal 2015 er 4,7% dårligere, end vi havde forventet (-6,3% ift. markedsforventningerne). Det skal dog bemærkes, at driftsresultatet i 2. kvartal er negativt påvirket af en nedskrivning på 50 mio. kr. Seneste analyse: relateret til Novozymes’ farmaceutiske forretning. Når der ses bort fra nedskrivningen er 17/04/15 – Aktieudsyn – Min- overskudsgraden i 2. kvartal på 28,4%, hvilket er markant over vores estimat på 26,8%. No- dre valuta-drevet nedjustering vozymes nedjusterer salgsprognosen for 2015. Novozymes forventer nu, at salget vil vokse på vej 13-16% i danske kroner i 2015 mod tidligere 16-18%. I lokal valuta forventer Novozymes, at salget vil vokse med 4-7% mod tidligere 7-9%. Den stærke udvikling i indtjeningen i årets første seks måneder betyder, at Novozymes fastholder indtjeningsprognosen for 2015 på trods af den svagere salgsudvikling. Kalender: 22/10/15 – 3. kvartalsregnskab Hård konkurrence bland nordamerikanske vaskemiddelproducenter skaber udfordringer 19/01/16 – Årsregnskab 2015 Omsætningen fra vaskemiddelenzymer er 2% under vores estimat.
    [Show full text]
  • Jyske Bank Q4 2020
    Jyske Bank Q4 2020 23 February 2021 2020 in brief Clients experienced Negative rates – for better or worse All Progress Counts A changing organisation • More online meetings. • More clients began to invest • Own wind turbine to offset CO2 • An organisational change in the instead of having cash deposits. emission from direct and development organisation with • More specialists. indirect power consumption a view to becoming even more • To an increasing degree, the covered by means of own agile. • Fewer branches to visit. negative interest rate renewable energy production. environment was reflected in • Organisational changes in • A brand new mobile banking deposit rates for personal • First estimate of CO e emission Personal Clients to become platform. 2 clients. from business volumes. more focused and specialized. • Increased flexibility with Jyske • Targets for sustainability in all Frihed. • Advantageous interest rates • Many employees experienced and remortgaging opportunities material business areas. changed working conditions due for home owners remained. to COVID-19. • Energy loans and CO2 calculator facilitating energy retrofitting. • The sale of Jyske Bank Gibraltar • A new equity fund offering more was finalized. sustainable investment solutions. • New VISA card without Dankort. COVID-19 • Lockdown and restrictions affected Danish society in 2020. • Clients received individual advice and guidance about the COVID-19 situation. • Jyske Bank's employees were most flexible and adaptive, and the bank remained accessible. • A COVID-19
    [Show full text]
  • Remuneration for Bank Executives
    Remuneration for bank execu- tives A study on the impacts of corporate governance codes on executive re- muneration in Sweden, Denmark and the United Kingdom between 2004 and 2010 Degree Project within Business Administration Author: Andreas Klang and Niclas Kristoferson Tutor: Assoc. Prof. Dr. Dr. Petra Inwinkl Jönköping May 2011 Acknowledgements The process of this degree project, would not have been what it is without a number of people whom have contributed and played a part in shaping it to what it is today We would like to thank our tutor Assoc. Prof. Dr. Dr. Petra Inwinkl for herr advice and guidance throughout the process of the whole thesis. This thesis would not have been the same without her influential ideas and constructive criticism. We would also like to thank our seminare partners for their constructive feedback dur- ing all seminars. At last we would like to thank our families and girlfriends whom have endure us during the past six months with constant support and love. Andreas Klang Niclas Kristoferson Division of work The authors of the Remuneration for bank executives, a study on the impacts of corporate go- vernance codes on executive remuneration in Sweden, Denmark and the United Kingdom be- tween 2004 and 2010 are Andreas Klang and Niclas Kristoferson. Andreas Klang have done fif- ty per cent and Niclas Kristoferson have done fifty per cent. Degree Project within Business Administration Title: Remuneration for Bank Executive- A study on the impacts of corporate governance on executive remuneration Author: Andreas Klang and Niclas Kristoferson Tutor: Assoc. Prof. Dr. Dr.
    [Show full text]